Seres Therapeutics

Seres Therapeutics

MCRB· Manufacturing· Fiscal year ends in December

No proxy on file names the CEO of Seres Therapeutics.

Executives5

See all
  1. 1Eric D. ShaffFY2025
  2. 2Thomas J. DesRosierFY2025
  3. 3Marella ThorellFY2025
  4. 4Teresa L. Young, Ph.D.FY2025
  5. 5Matthew Henn, Ph.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Seres Therapeutics paid its 5 named executives $6.1M in total in FY2025 (Dec).

Name
Eric D. ShaffFormer President and Chief Executive Officer
Thomas J. DesRosierFormer Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal OfficerNot disclosed
Marella ThorellFormer Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Financial OfficerNot disclosedNot disclosed
Teresa L. Young, Ph.D.Former Executive Vice President and Chief Commercial and Strategy OfficerNot disclosed
Matthew Henn, Ph.D.President and Chief Scientific OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers18

See all

The FY2024 (Dec) proxy of Seres Therapeutics names 18 peer companies for pay. Pay versus performance data of Seres Therapeutics for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Willard H. Dere, M.D.Director · 8 yr on the boardIndependentAudit (Chair), Science and Clinical Development—Paid as an executive
  • Kurt C. GravesDirector · 4 yr on the boardIndependentCompensation and Talent (Chair)—Paid as an executive
  • Robert RosielloDirector · 0 yr on the boardIndependentCompensation and Talent—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 27, 2026FY2025
Annual report10-KMar 12, 2026FY2025
Annual report10-KMar 13, 2025FY2024
Proxy statementDEF 14AMar 13, 2025FY2024
Annual report10-KMar 5, 2024FY2023
Proxy statementDEF 14AMar 5, 2024FY2023